Early data from the phase III CheckMate 067 trial, reported in September 2017, showed that patients with advanced melanoma treated with nivolumab, with or without ipilimumab, maintained their quality of life for at least a year. Recently reported long-term data from the study show the trend continues. In addition to better survival rates, the researchers noted that combination therapy with nivolumab and ipilimumab may provide advanced melanoma patients with a good quality of life, even 4 years post-treatment.

Learn more by clicking here.